RARE
NASDAQ · Biotechnology
Ultragenyx Pharmaceutical In
$24.77
+0.08 (+0.32%)
Performance
1D
—
1W
—
1M
—
3M
+3.73%
6M
-22.45%
1Y
-29.45%
YTD
+4.96%
Open$24.90
Previous Close$24.69
Day High$25.12
Day Low$24.37
52W High$42.37
52W Low$18.29
Volume—
Avg Volume1.91M
Market Cap2.57B
P/E Ratio—
EPS$-5.83
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$26.56
Below
SMA 200
$31.06
Below
RSI (14)
37.4
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Strong Buy
26 analysts
Price Target
+200.5% upside
Current
$24.77
$24.77
Target
$74.44
$74.44
$68.49
$74.44 avg
$103.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 708.75M | 577.11M | 933.24M |
| Net Income | -605,536,699 | -443,761,118 | 54.30M |
| Profit Margin | -85.4% | -81.2% | 5.8% |
| EBITDA | -553,940,021 | -428,501,766 | 81.20M |
| Free Cash Flow | — | — | 84.57M |
| Rev Growth | +22.8% | +22.8% | -2.9% |
| Debt/Equity | 3.41 | 3.41 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |